<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00305253</url>
  </required_header>
  <id_info>
    <org_study_id>05-84956-000-GSS</org_study_id>
    <nct_id>NCT00305253</nct_id>
  </id_info>
  <brief_title>Efficacy Study of the Non-Pneumatic Anti-Shock Garment (NASG) in Egypt</brief_title>
  <official_title>Efficacy Study of the Non-Pneumatic Anti-Shock Garment (NASG) in Egypt</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MacArthur Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the efficacy of the NASG on women suffering from obstetric hemorrhage as
      compared to hemorrhaging women who do not receive the NASG.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a comparative, pre-post study of the Non-pneumatic Anti-Shock Garment (NASG) to
      establish its effectiveness in reducing maternal mortality and morbidity due to obstetrical
      hemorrhage. The sites are two maternity teaching hospitals in Egypt: El Galaa, in Cairo and
      Assiut University in Assiut.

      Our main aim was to test the efficacy of the NASG on women suffering from obstetric
      hemorrhage as compared to hemorrhaging women who do not receive the NASG. Our primary outcome
      was Extreme Adverse Outcomes (EAO) - a combined outcome of maternal mortality and severe
      morbidity. Secondary outcomes included mean measured blood loss and incidence of emergency
      hysterectomy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Extreme Adverse Outcomes (EAO) - a Combined Outcome of Maternal Mortality or Severe Morbidity (Cardiac,Respiratory, Renal or Cerebral Dysfunction)</measure>
    <time_frame>from early pregnancy to within 3 weeks postpartum</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Loss Due to Obstetric Hemorrhage</measure>
    <time_frame>within 72 hours of study enrollment</time_frame>
    <description>cumulative blood loss measured hourly upon study admission by calibrated blood collection drape</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency Hysterectomy</measure>
    <time_frame>within 72 hours of study enrollment</time_frame>
    <description>incidence of emergency hysterectomy for cases of uterine atony</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">990</enrollment>
  <condition>Hypovolemic Shock</condition>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Pre-Intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The Pre-Intervention Phase served as the Control / Baseline group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention used in this phase and outcomes compared to the Pre-Intervention phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-pneumatic Anti-shock Garment (NASG)</intervention_name>
    <description>In the Post-Intrevention phase of the study, the NASG will be used when a patient meets the study criteria.</description>
    <arm_group_label>Post-Intervention</arm_group_label>
    <other_name>NASG</other_name>
    <other_name>Manufactured by Zoex</other_name>
    <other_name>Anti-Shock Garment</other_name>
    <other_name>Life Wrap</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  blood loss from obstetric hemorrhage &gt;= 1000 mL

          -  pulse &gt; 100 beats per minute or systolic blood pressure &lt; 100 mmHg

        Exclusion Criteria:

        Absolute exclusion criteria:

          -  current viable third trimester intrauterine pregnancy that can be delivered in the
             next 20 minutes after hemorrhage begins

          -  current bleeding sites above the diaphragm.

        Relative exclusion criteria:

          -  history or current clinical evidence of mitral stenosis or congestive heart failure
             (CHF)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suellen Miller, CNM, PhD, RN</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assuit University Hospital</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El-Galaa Teaching Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://www.lifewrap.org</url>
    <description>Information and updates on current trials using the Life Wrap (NASG) for obstetric hemorrhage in low resource settings.</description>
  </link>
  <results_reference>
    <citation>Miller S, Hamza S, Bray EH, Lester F, Nada K, Gibson R, Fathalla M, Mourad M, Fathy A, Turan JM, Dau KQ, Nasshar I, Elshair I, Hensleigh P. First aid for obstetric haemorrhage: the pilot study of the non-pneumatic anti-shock garment in Egypt. BJOG. 2006 Apr;113(4):424-9.</citation>
    <PMID>16553654</PMID>
  </results_reference>
  <results_reference>
    <citation>Miller S, Martin HB, Morris JL. Anti-shock garment in postpartum haemorrhage. Best Pract Res Clin Obstet Gynaecol. 2008 Dec;22(6):1057-74. doi: 10.1016/j.bpobgyn.2008.08.008. Epub 2008 Sep 20. Review.</citation>
    <PMID>18805742</PMID>
  </results_reference>
  <results_reference>
    <citation>Turan J, Ojengbede O, Fathalla M, Mourad-Youssif M, Morhason-Bello IO, Nsima D, Morris J, Butrick E, Martin H, Camlin C, Miller S. Positive effects of the non-pneumatic anti-shock garment on delays in accessing care for postpartum and postabortion hemorrhage in Egypt and Nigeria. J Womens Health (Larchmt). 2011 Jan;20(1):91-8. doi: 10.1089/jwh.2010.2081. Epub 2010 Dec 29.</citation>
    <PMID>21190486</PMID>
  </results_reference>
  <results_reference>
    <citation>Miller S, Fathalla MM, Ojengbede OA, Camlin C, Mourad-Youssif M, Morhason-Bello IO, Galadanci H, Nsima D, Butrick E, Al Hussaini T, Turan J, Meyer C, Martin H, Mohammed AI. Obstetric hemorrhage and shock management: using the low technology Non-pneumatic Anti-Shock Garment in Nigerian and Egyptian tertiary care facilities. BMC Pregnancy Childbirth. 2010 Oct 18;10:64. doi: 10.1186/1471-2393-10-64.</citation>
    <PMID>20955600</PMID>
  </results_reference>
  <results_reference>
    <citation>Mourad-Youssif M, Ojengbede OA, Meyer CD, Fathalla M, Morhason-Bello IO, Galadanci H, Camlin C, Nsima D, Al Hussaini T, Butrick E, Miller S. Can the Non-pneumatic Anti-Shock Garment (NASG) reduce adverse maternal outcomes from postpartum hemorrhage? Evidence from Egypt and Nigeria. Reprod Health. 2010 Sep 1;7:24. doi: 10.1186/1742-4755-7-24.</citation>
    <PMID>20809942</PMID>
  </results_reference>
  <results_reference>
    <citation>Miller S, Turan JM, Dau K, Fathalla M, Mourad M, Sutherland T, Hamza S, Lester F, Gibson EB, Gipson R, Nada K, Hensleigh P. Use of the non-pneumatic anti-shock garment (NASG) to reduce blood loss and time to recovery from shock for women with obstetric haemorrhage in Egypt. Glob Public Health. 2007;2(2):110-24. doi: 10.1080/17441690601012536.</citation>
    <PMID>19280394</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2006</study_first_submitted>
  <study_first_submitted_qc>March 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2006</study_first_posted>
  <results_first_submitted>July 7, 2009</results_first_submitted>
  <results_first_submitted_qc>June 18, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 15, 2011</results_first_posted>
  <last_update_submitted>May 9, 2013</last_update_submitted>
  <last_update_submitted_qc>May 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>maternal mortality</keyword>
  <keyword>obstetric hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Hypovolemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pre-Intervention</title>
          <description>Pre-intervention period: patients experiencing obstetric hemorrhage were treated with standardized evidence-based protocol.</description>
        </group>
        <group group_id="P2">
          <title>Post-Intervention</title>
          <description>Post-intervention (NASG) period: patients experiencing obstetric hemorrhage were treated with standardized evidence-based protocol plus NASG.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="432"/>
                <participants group_id="P2" count="559"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="432"/>
                <participants group_id="P2" count="558"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pre-Intervention</title>
          <description>facilities will treat patients with standardized evidence-based protocol when a patient meets the study criteria.</description>
        </group>
        <group group_id="B2">
          <title>Post-Intervention</title>
          <description>facilities will treat patients with standardized evidence-based protocol plus NASG when a patient meets the study criteria.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="432"/>
            <count group_id="B2" value="558"/>
            <count group_id="B3" value="990"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.7" spread="6.2"/>
                    <measurement group_id="B2" value="28.9" spread="6.0"/>
                    <measurement group_id="B3" value="28.8" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="432"/>
                    <measurement group_id="B2" value="558"/>
                    <measurement group_id="B3" value="990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Egypt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="432"/>
                    <measurement group_id="B2" value="558"/>
                    <measurement group_id="B3" value="990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Extreme Adverse Outcomes (EAO) - a Combined Outcome of Maternal Mortality or Severe Morbidity (Cardiac,Respiratory, Renal or Cerebral Dysfunction)</title>
        <time_frame>from early pregnancy to within 3 weeks postpartum</time_frame>
        <population>All patients enrolled in the study were used in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Intervention</title>
            <description>facilities will treat patients with standardized evidence-based protocol when a patient meets the study criteria.</description>
          </group>
          <group group_id="O2">
            <title>Post-Intervention</title>
            <description>facilities will treat patients with standardized evidence-based protocol plus NASG when a patient meets the study criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Extreme Adverse Outcomes (EAO) - a Combined Outcome of Maternal Mortality or Severe Morbidity (Cardiac,Respiratory, Renal or Cerebral Dysfunction)</title>
          <population>All patients enrolled in the study were used in this analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
                <count group_id="O2" value="558"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Relative risks and confidence intervals were computed for the primary outcome, Extreme Adverse Outcomes (EAO) - a combined measure of maternal mortality or severe mobidity.
To estimate the independent effect of the intervention net of the effects of other baseline characteristics, a multiple logistic regression model was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Independent variables were selected on the basis of their significant association with EAO in bivariate analyses (t-tests and logistic regression).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
            <estimate_desc>Pre-Intervention group was compared to the Post-Intervention group. Each group contained different study participants.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Loss Due to Obstetric Hemorrhage</title>
        <description>cumulative blood loss measured hourly upon study admission by calibrated blood collection drape</description>
        <time_frame>within 72 hours of study enrollment</time_frame>
        <population>Blood loss information was missing on some patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Intervention</title>
            <description>facilities will treat patients with standardized evidence-based protocol when a patient meets the study criteria.</description>
          </group>
          <group group_id="O2">
            <title>Post-Intervention</title>
            <description>facilities will treat patients with standardized evidence-based protocol plus NASG when a patient meets the study criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Loss Due to Obstetric Hemorrhage</title>
          <description>cumulative blood loss measured hourly upon study admission by calibrated blood collection drape</description>
          <population>Blood loss information was missing on some patients.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="435"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378.9" spread="234.3"/>
                    <measurement group_id="O2" value="253.2" spread="205.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mean measured volume of blood loss in the drape was compared across phases with t-tests.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Pre-Intervention group was compared to the Post-Intervention group. Each group contained different study participants.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emergency Hysterectomy</title>
        <description>incidence of emergency hysterectomy for cases of uterine atony</description>
        <time_frame>within 72 hours of study enrollment</time_frame>
        <population>Data on emergency hysterectomy are only for women with diagnosis of uterine atony.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-Intervention</title>
            <description>facilities will treat patients with standardized evidence-based protocol when a patient meets the study criteria.</description>
          </group>
          <group group_id="O2">
            <title>Post-Intervention</title>
            <description>facilities will treat patients with standardized evidence-based protocol plus NASG when a patient meets the study criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Emergency Hysterectomy</title>
          <description>incidence of emergency hysterectomy for cases of uterine atony</description>
          <population>Data on emergency hysterectomy are only for women with diagnosis of uterine atony.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Relative risks and confidence intervals were computed for emergency hysterectomy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
            <estimate_desc>Pre-Intervention group was compared to the Post-Intervention group. Each group contained different study participants.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pre-Intervention</title>
          <description>facilities will treat patients with standardized evidence-based protocol when a patient meets the study criteria.</description>
        </group>
        <group group_id="E2">
          <title>Post-Intervention</title>
          <description>facilities will treat patients with standardized evidence-based protocol plus NASG when a patient meets the study criteria.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Mortality</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="432"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <description>Other adverse events are all designated as morbidities in publications. Three individuals in the pre-intervention group suffered two other adverse events each, but in analysis are considered single morbidities.</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="432"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respitory Distress Syndrome (ARDS)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="432"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="558"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Local PIs are required to review results with Dr. Miller before releasing.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Non-randomized, non-blinded pre-intervention/intervention design</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Suellen Miller</name_or_title>
      <organization>University of California San Francisco (UCSF)</organization>
      <phone>415 597 9394</phone>
      <email>smiller@globalhealth.ucsf.edu , suellenmiller@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

